Zenas BioPharma, Inc./$ZBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Ticker
$ZBIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
130
ISIN
US98937L1052
Website
ZBIO Metrics
BasicAdvanced
$401M
-
-$7.00
-
-
Price and volume
Market cap
$401M
52-week high
$12.56
52-week low
$6.11
Average daily volume
190K
Financial strength
Current ratio
6.468
Quick ratio
6.393
Long term debt to equity
0.111
Total debt to equity
0.431
Profitability
EBITDA (TTM)
-173.513
Gross margin (TTM)
-909.39%
Net profit margin (TTM)
-1,085.07%
Operating margin (TTM)
-1,157.60%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-56.70%
Return on equity (TTM)
-115.47%
Valuation
Price to revenue (TTM)
14.856
Price to book
1.41
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-1.618
Free cash flow yield (TTM)
-61.82%
Free cash flow per share (TTM)
-592.20%
Growth
Revenue change (TTM)
-70.00%
Earnings per share change (TTM)
-76.46%
Bulls say / Bears say
Zenas BioPharma successfully raised approximately $258.7 million through its upsized initial public offering, providing substantial capital to advance its lead candidate, obexelimab, and support its growth strategy. (globenewswire.com)
Analysts from Wolfe Research and Wedbush have initiated coverage of Zenas BioPharma with 'Outperform' recommendations, indicating strong confidence in the company's future performance. (nasdaq.com, nasdaq.com)
Morgan Stanley has expressed a bullish outlook on Zenas BioPharma, citing positive momentum in obexelimab trials, which could lead to significant advancements in treating autoimmune diseases. (investing.com)
Zenas BioPharma is facing a class-action lawsuit alleging that the company overstated its operational funding duration in its IPO registration statement, potentially undermining investor confidence. (globenewswire.com)
The company reported a net loss of $156.99 million for the full year ended December 31, 2024, compared to a net loss of $37.12 million the previous year, indicating escalating financial challenges. (marketscreener.com)
Recent financial disclosures reveal a significant uptick in current liabilities, leading to a sharp decline in the company's Quick Ratio to 6.12, raising concerns about its short-term financial health. (csimarket.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
ZBIO News
AllArticlesVideos
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
Accesswire·2 weeks ago
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $401M as of July 01, 2025.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of July 01, 2025.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.